Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.

Kosiborod MN, Esterline R, Oscarsson J, Gasparyan SB, Furtado RHM, Verma S, Berwanger O

Open source

DOI
10.1016/s2213-8587(21)00326-0
Published
2022 Feb
Container
The lancet. Diabetes & endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2213-8587-21-00326-0,
  title = {Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.},
  author = {Kosiborod MN and Esterline R and Oscarsson J and Gasparyan SB and Furtado RHM and Verma S and Berwanger O},
  year = {2022},
  journal = {The lancet. Diabetes \& endocrinology},
  doi = {10.1016/s2213-8587(21)00326-0},
  url = {https://doi.org/10.1016/s2213-8587(21)00326-0}
}

RIS

TY  - JOUR
TI  - Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.
AU  - Kosiborod MN
AU  - Esterline R
AU  - Oscarsson J
AU  - Gasparyan SB
AU  - Furtado RHM
AU  - Verma S
AU  - Berwanger O
PY  - 2022
JO  - The lancet. Diabetes & endocrinology
DO  - 10.1016/s2213-8587(21)00326-0
UR  - https://doi.org/10.1016/s2213-8587(21)00326-0
ER  - 

APA

MN, K., R, E., J, O., SB, G., RHM, F., S, V., & O, B. (2022). Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(21)00326-0

Source records